nodes	percent_of_prediction	percent_of_DWPC	metapath
Dihydroergotamine—HTR1A—Parkinson's disease	0.548	0.7	CbGaD
Dihydroergotamine—ABCB1—Parkinson's disease	0.235	0.3	CbGaD
Dihydroergotamine—HTR1B—telencephalic ventricle—Parkinson's disease	0.00529	0.0841	CbGeAlD
Dihydroergotamine—HTR1D—telencephalic ventricle—Parkinson's disease	0.00512	0.0814	CbGeAlD
Dihydroergotamine—HTR1A—telencephalic ventricle—Parkinson's disease	0.00427	0.0679	CbGeAlD
Dihydroergotamine—ADRA2A—peripheral nervous system—Parkinson's disease	0.00242	0.0385	CbGeAlD
Dihydroergotamine—HTR6—forebrain—Parkinson's disease	0.00229	0.0364	CbGeAlD
Dihydroergotamine—Ergoloid mesylate—DRD1—Parkinson's disease	0.0021	0.211	CrCbGaD
Dihydroergotamine—HTR1A—hindbrain—Parkinson's disease	0.00202	0.032	CbGeAlD
Dihydroergotamine—Ergoloid mesylate—DRD2—Parkinson's disease	0.00148	0.149	CrCbGaD
Dihydroergotamine—HTR1B—brainstem—Parkinson's disease	0.00143	0.0228	CbGeAlD
Dihydroergotamine—HTR1D—brainstem—Parkinson's disease	0.00139	0.022	CbGeAlD
Dihydroergotamine—HTR1B—forebrain—Parkinson's disease	0.00138	0.022	CbGeAlD
Dihydroergotamine—HTR1D—forebrain—Parkinson's disease	0.00134	0.0213	CbGeAlD
Dihydroergotamine—HTR6—head—Parkinson's disease	0.00131	0.0209	CbGeAlD
Dihydroergotamine—HTR6—nervous system—Parkinson's disease	0.00124	0.0198	CbGeAlD
Dihydroergotamine—HTR2B—forebrain—Parkinson's disease	0.00124	0.0198	CbGeAlD
Dihydroergotamine—HTR6—central nervous system—Parkinson's disease	0.0012	0.019	CbGeAlD
Dihydroergotamine—HTR1B—cardiovascular system—Parkinson's disease	0.00117	0.0186	CbGeAlD
Dihydroergotamine—HTR1A—brainstem—Parkinson's disease	0.00116	0.0184	CbGeAlD
Dihydroergotamine—HTR1D—cardiovascular system—Parkinson's disease	0.00113	0.018	CbGeAlD
Dihydroergotamine—HTR1A—forebrain—Parkinson's disease	0.00111	0.0177	CbGeAlD
Dihydroergotamine—HTR2B—cardiovascular system—Parkinson's disease	0.00105	0.0167	CbGeAlD
Dihydroergotamine—HTR6—brain—Parkinson's disease	0.000951	0.0151	CbGeAlD
Dihydroergotamine—HTR1A—cardiovascular system—Parkinson's disease	0.000943	0.015	CbGeAlD
Dihydroergotamine—HTR1B—midbrain—Parkinson's disease	0.000912	0.0145	CbGeAlD
Dihydroergotamine—HTR1B—spinal cord—Parkinson's disease	0.00089	0.0141	CbGeAlD
Dihydroergotamine—HTR1D—midbrain—Parkinson's disease	0.000883	0.014	CbGeAlD
Dihydroergotamine—Bromocriptine—HTR7—Parkinson's disease	0.000857	0.086	CrCbGaD
Dihydroergotamine—Bromocriptine—DRD3—Parkinson's disease	0.000806	0.0809	CrCbGaD
Dihydroergotamine—HTR1B—head—Parkinson's disease	0.000791	0.0126	CbGeAlD
Dihydroergotamine—Bromocriptine—DRD1—Parkinson's disease	0.000791	0.0794	CrCbGaD
Dihydroergotamine—ADRA2A—forebrain—Parkinson's disease	0.000781	0.0124	CbGeAlD
Dihydroergotamine—HTR1D—head—Parkinson's disease	0.000766	0.0122	CbGeAlD
Dihydroergotamine—HTR1B—nervous system—Parkinson's disease	0.00075	0.0119	CbGeAlD
Dihydroergotamine—HTR1A—midbrain—Parkinson's disease	0.000736	0.0117	CbGeAlD
Dihydroergotamine—HTR1D—nervous system—Parkinson's disease	0.000726	0.0115	CbGeAlD
Dihydroergotamine—HTR1B—central nervous system—Parkinson's disease	0.000722	0.0115	CbGeAlD
Dihydroergotamine—HTR1A—spinal cord—Parkinson's disease	0.000718	0.0114	CbGeAlD
Dihydroergotamine—HTR2B—head—Parkinson's disease	0.000712	0.0113	CbGeAlD
Dihydroergotamine—HTR1D—central nervous system—Parkinson's disease	0.000699	0.0111	CbGeAlD
Dihydroergotamine—Ergotamine—HTR1A—Parkinson's disease	0.000681	0.0684	CrCbGaD
Dihydroergotamine—HTR2B—nervous system—Parkinson's disease	0.000676	0.0107	CbGeAlD
Dihydroergotamine—Bromocriptine—HTR1A—Parkinson's disease	0.000657	0.0659	CrCbGaD
Dihydroergotamine—HTR2B—central nervous system—Parkinson's disease	0.00065	0.0103	CbGeAlD
Dihydroergotamine—HTR1A—head—Parkinson's disease	0.000638	0.0101	CbGeAlD
Dihydroergotamine—HTR1A—nervous system—Parkinson's disease	0.000605	0.00962	CbGeAlD
Dihydroergotamine—HTR1A—central nervous system—Parkinson's disease	0.000583	0.00926	CbGeAlD
Dihydroergotamine—Ergotamine—DRD2—Parkinson's disease	0.000578	0.058	CrCbGaD
Dihydroergotamine—HTR1B—brain—Parkinson's disease	0.000573	0.00911	CbGeAlD
Dihydroergotamine—HTR1A—cerebellum—Parkinson's disease	0.00057	0.00905	CbGeAlD
Dihydroergotamine—ADRA2A—medulla oblongata—Parkinson's disease	0.000565	0.00897	CbGeAlD
Dihydroergotamine—Bromocriptine—DRD2—Parkinson's disease	0.000557	0.056	CrCbGaD
Dihydroergotamine—HTR1D—brain—Parkinson's disease	0.000555	0.00882	CbGeAlD
Dihydroergotamine—HTR2B—brain—Parkinson's disease	0.000516	0.00821	CbGeAlD
Dihydroergotamine—ADRA2A—midbrain—Parkinson's disease	0.000516	0.0082	CbGeAlD
Dihydroergotamine—ADRA2A—spinal cord—Parkinson's disease	0.000503	0.008	CbGeAlD
Dihydroergotamine—ABCB1—embryo—Parkinson's disease	0.000492	0.00782	CbGeAlD
Dihydroergotamine—HTR1A—brain—Parkinson's disease	0.000463	0.00735	CbGeAlD
Dihydroergotamine—ADRA2A—head—Parkinson's disease	0.000447	0.00711	CbGeAlD
Dihydroergotamine—Ergotamine—HTR2A—Parkinson's disease	0.000447	0.0449	CrCbGaD
Dihydroergotamine—ABCB1—forebrain—Parkinson's disease	0.000435	0.00692	CbGeAlD
Dihydroergotamine—Bromocriptine—HTR2A—Parkinson's disease	0.000431	0.0432	CrCbGaD
Dihydroergotamine—ADRA2A—nervous system—Parkinson's disease	0.000424	0.00674	CbGeAlD
Dihydroergotamine—ADRA2A—central nervous system—Parkinson's disease	0.000408	0.00649	CbGeAlD
Dihydroergotamine—ADRA2A—cerebellum—Parkinson's disease	0.000399	0.00634	CbGeAlD
Dihydroergotamine—ABCB1—cardiovascular system—Parkinson's disease	0.000368	0.00585	CbGeAlD
Dihydroergotamine—CYP3A4—nervous system—Parkinson's disease	0.000334	0.00531	CbGeAlD
Dihydroergotamine—ADRA2A—brain—Parkinson's disease	0.000324	0.00515	CbGeAlD
Dihydroergotamine—CYP3A4—central nervous system—Parkinson's disease	0.000322	0.00511	CbGeAlD
Dihydroergotamine—ABCB1—medulla oblongata—Parkinson's disease	0.000315	0.005	CbGeAlD
Dihydroergotamine—Ergotamine—ABCB1—Parkinson's disease	0.000292	0.0293	CrCbGaD
Dihydroergotamine—ABCB1—midbrain—Parkinson's disease	0.000288	0.00457	CbGeAlD
Dihydroergotamine—Bromocriptine—ABCB1—Parkinson's disease	0.000281	0.0282	CrCbGaD
Dihydroergotamine—ABCB1—spinal cord—Parkinson's disease	0.000281	0.00446	CbGeAlD
Dihydroergotamine—ABCB1—head—Parkinson's disease	0.000249	0.00396	CbGeAlD
Dihydroergotamine—ABCB1—nervous system—Parkinson's disease	0.000236	0.00376	CbGeAlD
Dihydroergotamine—ABCB1—central nervous system—Parkinson's disease	0.000228	0.00362	CbGeAlD
Dihydroergotamine—ABCB1—cerebellum—Parkinson's disease	0.000222	0.00354	CbGeAlD
Dihydroergotamine—ABCB1—brain—Parkinson's disease	0.000181	0.00287	CbGeAlD
Dihydroergotamine—ADRA2A—Signaling by GPCR—ADORA2A—Parkinson's disease	3.89e-05	0.000269	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—ADORA2A—Parkinson's disease	3.84e-05	0.000265	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—EDN1—Parkinson's disease	3.82e-05	0.000264	CbGpPWpGaD
Dihydroergotamine—HTR6—GPCR downstream signaling—HTR2A—Parkinson's disease	3.79e-05	0.000261	CbGpPWpGaD
Dihydroergotamine—HTR2B—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—Parkinson's disease	3.77e-05	0.00026	CbGpPWpGaD
Dihydroergotamine—HTR1D—GPCR downstream signaling—HTR2A—Parkinson's disease	3.76e-05	0.000259	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—ADRBK1—Parkinson's disease	3.75e-05	0.000259	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—GRK5—Parkinson's disease	3.74e-05	0.000258	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—FGF20—Parkinson's disease	3.72e-05	0.000257	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—HTR1A—Parkinson's disease	3.72e-05	0.000257	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—PDYN—Parkinson's disease	3.7e-05	0.000255	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—DDC—Parkinson's disease	3.69e-05	0.000254	CbGpPWpGaD
Dihydroergotamine—HTR1B—GPCR downstream signaling—HTR2A—Parkinson's disease	3.68e-05	0.000254	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—TAC1—Parkinson's disease	3.66e-05	0.000253	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—INSR—Parkinson's disease	3.65e-05	0.000252	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—DRD2—Parkinson's disease	3.64e-05	0.000251	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—HTR7—Parkinson's disease	3.64e-05	0.000251	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—INSR—Parkinson's disease	3.62e-05	0.00025	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—ADORA2A—Parkinson's disease	3.61e-05	0.000249	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—DRD1—Parkinson's disease	3.59e-05	0.000248	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—EDN1—Parkinson's disease	3.59e-05	0.000248	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—INSR—Parkinson's disease	3.55e-05	0.000245	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—GFAP—Parkinson's disease	3.48e-05	0.00024	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—DRD3—Parkinson's disease	3.48e-05	0.00024	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—GSTA4—Parkinson's disease	3.48e-05	0.00024	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—GBA—Parkinson's disease	3.47e-05	0.00024	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—DBH—Parkinson's disease	3.47e-05	0.00024	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—FBP1—Parkinson's disease	3.47e-05	0.00024	CbGpPWpGaD
Dihydroergotamine—HTR2B—GPCR downstream signaling—HTR2A—Parkinson's disease	3.46e-05	0.000239	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—FGB—Parkinson's disease	3.45e-05	0.000238	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—GRM5—Parkinson's disease	3.44e-05	0.000238	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—HTR2A—Parkinson's disease	3.44e-05	0.000237	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—HTR1A—Parkinson's disease	3.43e-05	0.000237	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—FGB—Parkinson's disease	3.42e-05	0.000236	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—HTR2A—Parkinson's disease	3.41e-05	0.000236	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—HTR1A—Parkinson's disease	3.4e-05	0.000235	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—HTR1A—Parkinson's disease	3.38e-05	0.000233	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—TAC1—Parkinson's disease	3.38e-05	0.000233	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—GRM4—Parkinson's disease	3.36e-05	0.000232	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—TAC1—Parkinson's disease	3.35e-05	0.000231	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—FGB—Parkinson's disease	3.35e-05	0.000231	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—HTR2A—Parkinson's disease	3.34e-05	0.000231	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—HTR1A—Parkinson's disease	3.33e-05	0.00023	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—INSR—Parkinson's disease	3.33e-05	0.00023	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—TAC1—Parkinson's disease	3.33e-05	0.00023	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—DRD1—Parkinson's disease	3.31e-05	0.000229	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—DRD1—Parkinson's disease	3.29e-05	0.000227	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—TAC1—Parkinson's disease	3.28e-05	0.000227	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—DRD1—Parkinson's disease	3.26e-05	0.000225	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—ADRBK1—Parkinson's disease	3.25e-05	0.000224	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—DRD1—Parkinson's disease	3.22e-05	0.000222	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—DRD3—Parkinson's disease	3.21e-05	0.000221	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR downstream signaling—EDN1—Parkinson's disease	3.21e-05	0.000221	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—DRD3—Parkinson's disease	3.18e-05	0.00022	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—PENK—Parkinson's disease	3.18e-05	0.00022	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—MAG—Parkinson's disease	3.18e-05	0.00022	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—DRD3—Parkinson's disease	3.16e-05	0.000218	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—FGB—Parkinson's disease	3.15e-05	0.000217	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—HTR7—Parkinson's disease	3.15e-05	0.000217	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—DRD2—Parkinson's disease	3.15e-05	0.000217	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—HTR2A—Parkinson's disease	3.14e-05	0.000217	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—PLA2G6—Parkinson's disease	3.13e-05	0.000216	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—HTR1A—Parkinson's disease	3.13e-05	0.000216	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—DRD3—Parkinson's disease	3.12e-05	0.000215	CbGpPWpGaD
Dihydroergotamine—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—Parkinson's disease	3.11e-05	0.000215	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—MAOB—Parkinson's disease	3.1e-05	0.000214	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—TAC1—Parkinson's disease	3.08e-05	0.000213	CbGpPWpGaD
Dihydroergotamine—ABCB1—Transmembrane transport of small molecules—SLC6A3—Parkinson's disease	3.03e-05	0.000209	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—DRD1—Parkinson's disease	3.02e-05	0.000209	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—FGF20—Parkinson's disease	3.02e-05	0.000208	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—ADRBK1—Parkinson's disease	3e-05	0.000207	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—ADRBK1—Parkinson's disease	2.97e-05	0.000205	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—ADRBK1—Parkinson's disease	2.95e-05	0.000204	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—DRD3—Parkinson's disease	2.93e-05	0.000202	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—ADORA2A—Parkinson's disease	2.93e-05	0.000202	CbGpPWpGaD
Dihydroergotamine—ABCB1—Transmembrane transport of small molecules—CYCS—Parkinson's disease	2.91e-05	0.000201	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—ADRBK1—Parkinson's disease	2.91e-05	0.000201	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—EDN1—Parkinson's disease	2.91e-05	0.000201	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—PDYN—Parkinson's disease	2.91e-05	0.000201	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—HTR7—Parkinson's disease	2.9e-05	0.0002	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—DRD2—Parkinson's disease	2.9e-05	0.0002	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—DRD2—Parkinson's disease	2.88e-05	0.000199	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—HTR7—Parkinson's disease	2.88e-05	0.000199	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—HTR7—Parkinson's disease	2.86e-05	0.000197	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—DRD2—Parkinson's disease	2.86e-05	0.000197	CbGpPWpGaD
Dihydroergotamine—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK8—Parkinson's disease	2.86e-05	0.000197	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—ND3—Parkinson's disease	2.82e-05	0.000195	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—MCCC1—Parkinson's disease	2.82e-05	0.000195	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—HTR7—Parkinson's disease	2.82e-05	0.000195	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—DRD2—Parkinson's disease	2.82e-05	0.000195	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR downstream signaling—HTR2A—Parkinson's disease	2.8e-05	0.000194	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—GFAP—Parkinson's disease	2.74e-05	0.000189	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—ADRBK1—Parkinson's disease	2.74e-05	0.000189	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—GRM5—Parkinson's disease	2.71e-05	0.000187	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—INSR—Parkinson's disease	2.7e-05	0.000186	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—TALDO1—Parkinson's disease	2.65e-05	0.000183	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—OMD—Parkinson's disease	2.65e-05	0.000183	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—HTR7—Parkinson's disease	2.65e-05	0.000183	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—DRD2—Parkinson's disease	2.65e-05	0.000183	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—FGB—Parkinson's disease	2.55e-05	0.000176	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—DDC—Parkinson's disease	2.55e-05	0.000176	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—HTR2A—Parkinson's disease	2.55e-05	0.000176	CbGpPWpGaD
Dihydroergotamine—ABCB1—Transmembrane transport of small molecules—HMOX1—Parkinson's disease	2.53e-05	0.000175	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—EDN1—Parkinson's disease	2.52e-05	0.000174	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—NDUFB11—Parkinson's disease	2.52e-05	0.000174	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—TAC1—Parkinson's disease	2.5e-05	0.000173	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—DRD1—Parkinson's disease	2.45e-05	0.000169	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—IGF2—Parkinson's disease	2.43e-05	0.000168	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—IGF2—Parkinson's disease	2.41e-05	0.000167	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—GSTA4—Parkinson's disease	2.41e-05	0.000166	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—GCH1—Parkinson's disease	2.4e-05	0.000166	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—DRD3—Parkinson's disease	2.38e-05	0.000164	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—FGF20—Parkinson's disease	2.37e-05	0.000164	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—IGF2—Parkinson's disease	2.36e-05	0.000163	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—IGF1R—Parkinson's disease	2.35e-05	0.000162	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—IGF1R—Parkinson's disease	2.33e-05	0.000161	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—EDN1—Parkinson's disease	2.32e-05	0.00016	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—EDN1—Parkinson's disease	2.31e-05	0.000159	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—CYP2D6—Parkinson's disease	2.31e-05	0.000159	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—ADORA2A—Parkinson's disease	2.3e-05	0.000159	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—EDN1—Parkinson's disease	2.29e-05	0.000158	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—IGF1R—Parkinson's disease	2.28e-05	0.000158	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—CTGF—Parkinson's disease	2.26e-05	0.000156	CbGpPWpGaD
Dihydroergotamine—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—Parkinson's disease	2.26e-05	0.000156	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—EDN1—Parkinson's disease	2.26e-05	0.000156	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—IGF2—Parkinson's disease	2.22e-05	0.000153	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—ADRBK1—Parkinson's disease	2.22e-05	0.000153	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—HTR2A—Parkinson's disease	2.2e-05	0.000152	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—PLA2G6—Parkinson's disease	2.17e-05	0.00015	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—HTR7—Parkinson's disease	2.15e-05	0.000148	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—DRD2—Parkinson's disease	2.15e-05	0.000148	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—IGF1R—Parkinson's disease	2.15e-05	0.000148	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—MAOB—Parkinson's disease	2.14e-05	0.000148	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—FBP1—Parkinson's disease	2.14e-05	0.000148	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—DBH—Parkinson's disease	2.14e-05	0.000148	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—GBA—Parkinson's disease	2.14e-05	0.000148	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—NGF—Parkinson's disease	2.13e-05	0.000147	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—INSR—Parkinson's disease	2.12e-05	0.000146	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—EDN1—Parkinson's disease	2.12e-05	0.000146	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—NGF—Parkinson's disease	2.12e-05	0.000146	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—CYP2E1—Parkinson's disease	2.11e-05	0.000145	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—NQO1—Parkinson's disease	2.08e-05	0.000144	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—NGF—Parkinson's disease	2.07e-05	0.000143	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—TH—Parkinson's disease	2.05e-05	0.000142	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—HTR2A—Parkinson's disease	2.03e-05	0.00014	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—HTR2A—Parkinson's disease	2.02e-05	0.000139	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—FGB—Parkinson's disease	2.01e-05	0.000138	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—HTR2A—Parkinson's disease	2e-05	0.000138	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—HTR1A—Parkinson's disease	2e-05	0.000138	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—HTR2A—Parkinson's disease	1.97e-05	0.000136	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—CYCS—Parkinson's disease	1.97e-05	0.000136	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—TAC1—Parkinson's disease	1.97e-05	0.000136	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—NGF—Parkinson's disease	1.95e-05	0.000134	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—DRD1—Parkinson's disease	1.93e-05	0.000133	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—APOE—Parkinson's disease	1.89e-05	0.00013	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—APOE—Parkinson's disease	1.88e-05	0.000129	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—DRD3—Parkinson's disease	1.87e-05	0.000129	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—HTR2A—Parkinson's disease	1.86e-05	0.000128	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—APOE—Parkinson's disease	1.84e-05	0.000127	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—IGF2—Parkinson's disease	1.8e-05	0.000124	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—COMT—Parkinson's disease	1.75e-05	0.000121	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—ADRBK1—Parkinson's disease	1.74e-05	0.00012	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—IGF1R—Parkinson's disease	1.74e-05	0.00012	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—GSTP1—Parkinson's disease	1.74e-05	0.00012	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—MAOA—Parkinson's disease	1.73e-05	0.00012	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—APOE—Parkinson's disease	1.72e-05	0.000119	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—EDN1—Parkinson's disease	1.72e-05	0.000119	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—HMOX1—Parkinson's disease	1.71e-05	0.000118	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—DRD2—Parkinson's disease	1.69e-05	0.000117	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—HTR7—Parkinson's disease	1.69e-05	0.000117	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—ABCB1—Parkinson's disease	1.65e-05	0.000114	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—INS—Parkinson's disease	1.61e-05	0.000111	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—INS—Parkinson's disease	1.6e-05	0.000111	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—GSTM1—Parkinson's disease	1.6e-05	0.00011	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—CYP2D6—Parkinson's disease	1.59e-05	0.00011	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—NGF—Parkinson's disease	1.58e-05	0.000109	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—DDC—Parkinson's disease	1.57e-05	0.000108	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—INS—Parkinson's disease	1.57e-05	0.000108	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—CTGF—Parkinson's disease	1.56e-05	0.000108	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—GPX1—Parkinson's disease	1.53e-05	0.000106	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—HTR2A—Parkinson's disease	1.5e-05	0.000104	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—GSTA4—Parkinson's disease	1.48e-05	0.000102	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—INS—Parkinson's disease	1.47e-05	0.000102	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—CYP2E1—Parkinson's disease	1.46e-05	0.000101	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—NQO1—Parkinson's disease	1.44e-05	9.95e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—TH—Parkinson's disease	1.42e-05	9.8e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—IGF2—Parkinson's disease	1.41e-05	9.76e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—MTHFR—Parkinson's disease	1.41e-05	9.74e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—APOE—Parkinson's disease	1.4e-05	9.65e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—IGF1R—Parkinson's disease	1.37e-05	9.44e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—CYCS—Parkinson's disease	1.36e-05	9.41e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—EDN1—Parkinson's disease	1.35e-05	9.33e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PLA2G6—Parkinson's disease	1.33e-05	9.21e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—MAOB—Parkinson's disease	1.32e-05	9.12e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—APOE—Parkinson's disease	1.31e-05	9.07e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—NGF—Parkinson's disease	1.24e-05	8.57e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—COMT—Parkinson's disease	1.21e-05	8.34e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—GSTP1—Parkinson's disease	1.2e-05	8.3e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—CASP3—Parkinson's disease	1.2e-05	8.29e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—MAOA—Parkinson's disease	1.2e-05	8.28e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—INS—Parkinson's disease	1.19e-05	8.25e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—IL6—Parkinson's disease	1.19e-05	8.24e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—CASP3—Parkinson's disease	1.19e-05	8.23e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—HMOX1—Parkinson's disease	1.19e-05	8.18e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—IL6—Parkinson's disease	1.18e-05	8.18e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—HTR2A—Parkinson's disease	1.18e-05	8.16e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—CASP3—Parkinson's disease	1.17e-05	8.06e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—IL6—Parkinson's disease	1.16e-05	8.01e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—INS—Parkinson's disease	1.12e-05	7.75e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—GSTM1—Parkinson's disease	1.1e-05	7.62e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—MAPK8—Parkinson's disease	1.1e-05	7.62e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—APOE—Parkinson's disease	1.1e-05	7.59e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—CASP3—Parkinson's disease	1.1e-05	7.57e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—MAPK8—Parkinson's disease	1.1e-05	7.56e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—IL6—Parkinson's disease	1.09e-05	7.52e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—MAPK8—Parkinson's disease	1.07e-05	7.41e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—GPX1—Parkinson's disease	1.06e-05	7.3e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—MAPK8—Parkinson's disease	1.01e-05	6.96e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—CYP2D6—Parkinson's disease	9.82e-06	6.78e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—MTHFR—Parkinson's disease	9.76e-06	6.74e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—CTGF—Parkinson's disease	9.64e-06	6.65e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—INS—Parkinson's disease	9.39e-06	6.48e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—APOE—Parkinson's disease	9.09e-06	6.27e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—CYP2E1—Parkinson's disease	8.98e-06	6.2e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—CASP3—Parkinson's disease	8.9e-06	6.14e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—NQO1—Parkinson's disease	8.88e-06	6.13e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—IL6—Parkinson's disease	8.84e-06	6.1e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—TH—Parkinson's disease	8.75e-06	6.04e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—CYCS—Parkinson's disease	8.4e-06	5.8e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—MAPK8—Parkinson's disease	8.18e-06	5.64e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—INS—Parkinson's disease	7.77e-06	5.36e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—COMT—Parkinson's disease	7.44e-06	5.14e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—GSTP1—Parkinson's disease	7.41e-06	5.11e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—MAOA—Parkinson's disease	7.39e-06	5.1e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—HMOX1—Parkinson's disease	7.31e-06	5.04e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—IL6—Parkinson's disease	7.05e-06	4.87e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—ABCB1—Parkinson's disease	7.01e-06	4.84e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—IL6—Parkinson's disease	7e-06	4.83e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CASP3—Parkinson's disease	6.99e-06	4.82e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—IL6—Parkinson's disease	6.95e-06	4.79e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—IL6—Parkinson's disease	6.85e-06	4.73e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—GSTM1—Parkinson's disease	6.81e-06	4.7e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—GPX1—Parkinson's disease	6.52e-06	4.5e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—IL6—Parkinson's disease	6.44e-06	4.44e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—MAPK8—Parkinson's disease	6.43e-06	4.43e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—MTHFR—Parkinson's disease	6.02e-06	4.15e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—APOE—Parkinson's disease	5.6e-06	3.86e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—IL6—Parkinson's disease	5.22e-06	3.6e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—INS—Parkinson's disease	4.78e-06	3.3e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—IL6—Parkinson's disease	4.1e-06	2.83e-05	CbGpPWpGaD
